Trials / Completed
CompletedNCT00203099
Safety and Efficacy Study of Copaxone Administered in Combination With N-Acetylcysteine
A Pilot, Multicenter, Open-label, One-group Study to Explore the Efficacy, Tolerability and Safety of the Combination of Glatiramer Acetate (GA) and N-Acetylcysteine (NAC) in Subjects With Relapsing Remitting Multiple Sclerosis (RR-MS)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the effect of the therapy combining GA and NAC on disease activity as reflected by MRI parameters while assessing tolerability and safety.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Glatiramer Acetate, N-Acetylcysteine | Subcutaneous glatiramer acetate 20 mg and concomitant oral administration of N-Acetylcysteine divided into two 2.5 g doses. |
Timeline
- Start date
- 2004-12-01
- Primary completion
- 2006-08-01
- Completion
- 2008-06-01
- First posted
- 2005-09-20
- Last updated
- 2012-05-14
Source: ClinicalTrials.gov record NCT00203099. Inclusion in this directory is not an endorsement.